Hospira (HSP) Slammed On Worries About Production Delays
Tweet
Share
E-mailGet Alerts HSP Hot Sheet
Join SI Premium – FREE
Shares of Hospira Inc. (NYSE: HSP) are under heavy pressure Tuesday after an analyst said the company may face widespread production delays as questions surrounded the manufacturing of propofol and liposyn.
Hospira fell 10 percent after RBC Capital warned of the delays, that may take years to correct. The FDA may obtain an decree to ensure the violations are fixed, the firm said.
A company spokesperson told Bloomberg the company "has an unwavering commitment to quality and safety" and is "working diligently to make sure we fully comply with the agency’s expectation."
Hospira fell 10 percent after RBC Capital warned of the delays, that may take years to correct. The FDA may obtain an decree to ensure the violations are fixed, the firm said.
A company spokesperson told Bloomberg the company "has an unwavering commitment to quality and safety" and is "working diligently to make sure we fully comply with the agency’s expectation."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Advance Auto Parts (AAP) PT Lowered to $52 at RBC Capital
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
Create E-mail Alert Related Categories
Corporate News, FDA, Trader TalkRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
